Skip to main content
. 2017 Dec 13;15(2):274–282. doi: 10.1111/iwj.12861

Table 2.

List of antibodies used in the study and their specifications

Antibody Dilution Standard Specification Source Immunolocalisation
Anti‐CD31 1:1000 ++ SC‐1506 Sta Cruz Biotech Cytoplasm
Anti‐VEGF 1:50 ++ Clone VG1 Neomarkers Cytoplasm
a

Statistically significant difference in the control group on days 14 and 28 (P = 0.001) and 14 and 35 days (P = 0.007).